AstraZeneca taps IQVIA to 'warp speed' its U.S. pandemic vaccine research

Operation Warp Speed is living up to its name as, under the project, one of the COVID-19 vaccine front-runners AstraZeneca is teaming up with life science services company IQVIA to boost its work on the shot.

Under the plan, financial details of which were not disclosed, contract research organization IQVIA and AstraZeneca come together to “drive faster delivery of clinical studies in the U.S. aimed at demonstrating efficacy of AstraZeneca’s potential COVID-19 vaccine, AZD1222,” the pair said in a brief update.